Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization

Bibliography

• Gratwohl A, Baldomero H, Passweg J. Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 2013;20:485-93
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bregni M, et al. European Group for Blood and Marrow Transplantation. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161-7
   PubMed Web of Science ®Google Scholar
• Berenson Ri, Andrews RG, Bensinger WI, et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988;81:951
   PubMed Web of Science ®Google Scholar
• Civin IC, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J Immunol 1984;133:157-1984
   PubMed Web of Science ®Google Scholar
• Tindle RW, Nichols RAB, Chan L, et al. A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow. Leuk Res 1985;9:1-9
   PubMed Web of Science ®Google Scholar
• Lu L, Walker D, Broxmeyer HE, et al. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with MY1O and major histocompatibility class II monoclonal antibodies. J Immunol 1987;139:1823
   PubMed Web of Science ®Google Scholar
• Brandt J, Baird N, Lu L, et al. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J Clin Invest 1988;82:1017
   PubMed Web of Science ®Google Scholar
• Bell AJ, Hamblin TI, Oscier DG. Peripheral blood stem cell autografting. Hematol Oncol 1987;5:45
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74(6):1905-14
   PubMed Web of Science ®Google Scholar
• Bensinger W, DiPersio JF, MacCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181-95
   PubMed Web of Science ®Google Scholar
• Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003;419-37
   Google Scholar
• Lemoli RM. New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis 2012;4(1):e2012066
   PubMedGoogle Scholar
• Molineux G, Kinstler O, Briddell B, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-34
   PubMed Web of Science ®Google Scholar
• Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003;14:259-64
   PubMed Web of Science ®Google Scholar
• Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003;30(4 Suppl 13):24-30
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Untch M, Skacel T, et al. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004;31(3 Suppl 8):27-34
   PubMed Web of Science ®Google Scholar
• Bakanay ŞM, Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transplant 2012;47(9):1154-63
   PubMed Web of Science ®Google Scholar
• Cline MJ, Golde DW. Mobilization of hematopoietic stem cells (CFU-C) into the peripheral blood of man by endotoxin. Exp Hematol 1977;5(3):186-90
   PubMed Web of Science ®Google Scholar
• Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4
   PubMed Web of Science ®Google Scholar
• Dyson PG, Jackson KA, McClure BJ, et al. Increased levels of megakaryocyte progenitors in peripheral blood mobilised by chemotherapy and/or haemopoietic growth factor protocols. Bone Marrow Transplant 1996;18:705-12
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011;86(4):277-88
   PubMed Web of Science ®Google Scholar
• Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer 2013;21:2925-32
   PubMed Web of Science ®Google Scholar
• Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-8
   PubMed Web of Science ®Google Scholar
• Martino M, Pratico G, Messina G, et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006;77:410
   PubMed Web of Science ®Google Scholar
• Musto P, Scalzulli PR, Terruzzi E, et al. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature. Leuk Res 2007;31:1487
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Levis A, et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010;21:1482
   PubMed Web of Science ®Google Scholar
• Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998;16:1547-53
   PubMed Web of Science ®Google Scholar
• Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059-64
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-55
   PubMed Web of Science ®Google Scholar
• André M, Baudoux E, Bron D, et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003;43:50-7
   PubMed Web of Science ®Google Scholar
• Demirer T, Ayli M, Ozcan M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colonystimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002;116:468-74
   PubMed Web of Science ®Google Scholar
• Kim S, Kim HJ, Park JS, et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005;84:742-7
   PubMed Web of Science ®Google Scholar
• To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilizaton strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56
   PubMed Web of Science ®Google Scholar
• Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9
   PubMed Web of Science ®Google Scholar
• Endo T, Sato N, Mogi Y, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:703-7
   PubMed Web of Science ®Google Scholar
• Smardova L, Engert A, Haverkamp H, et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005;46:1017-22
   PubMed Web of Science ®Google Scholar
• de Latour RP, Chaoui D, Bourhis JH, et al. Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma. Leuk Lymphoma 2007;48:897-904
   PubMed Web of Science ®Google Scholar
• To LB, Davy ML, Haylock DN, et al. Autotransplantation using peripheral blood stem cells mobilized by cyclophosphamide. Bone Marrow Transplant 1989;4(5):595-6
   PubMed Web of Science ®Google Scholar
• Indovina A, Liberti G, Majolino I, et al. Cyclophosphamide 4 g/m2 plus rhG-CSF for mobilization of circulating progenitor cells in malignant lymphomas. Int J Artif Organs 1993;16(Suppl 5):30-4
   PubMedGoogle Scholar
• Demuynck H, Delforge M, Verhoef G, et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995;90(2):384-92
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Guarini A, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;29(4):285-90
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001;27:837-42
   PubMed Web of Science ®Google Scholar
• Pucci G, Irrera G, Martino M, et al. High-dose etoposide enables the collection of peripheral blood stem cells in patients who failed cyclophosphamide-induced mobilization. Br J Haematol 1998;100:612-13
   PubMed Web of Science ®Google Scholar
• André M, Baudoux E, Bron D, et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003;43:50-7
   PubMed Web of Science ®Google Scholar
• Kim S, Kim HJ, Park JS, et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005;84:742-7
   PubMed Web of Science ®Google Scholar
• Ozcelik T, Topcuoglu P, Beksac M, et al. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF. Bone Marrow Transplant 2009;44:779-83
   PubMed Web of Science ®Google Scholar
• de Azevedo AM, Nucci M, Maiolino A, et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002;29:745-51
   PubMed Web of Science ®Google Scholar
• Pierelli L, Perseghin P, Marchetti M, et al. Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion 2012;52(4):893-905
   PubMed Web of Science ®Google Scholar
• Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colonystimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;8663:580-5
   Google Scholar
• Nowrousian MR, Waschke S, Bojko P, et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003;14(1):29-36
   PubMedGoogle Scholar
• Arora M, Burns LJ, Barker JN, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004;10:395-404
   PubMed Web of Science ®Google Scholar
• Kopf B, De Giorgi U, Vertogen B, et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006;38:407-12
   PubMed Web of Science ®Google Scholar
• Spitzer G, Adkins D, Mathews M, et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997;20:921-30
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998;91:3148-55
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilizaton strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14(9):1045-56
   PubMed Web of Science ®Google Scholar
• Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells – definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-9
   PubMed Web of Science ®Google Scholar
• Perseghin P, Terruzzi E, Dassi M, et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009;41:33-7
   PubMed Web of Science ®Google Scholar
• Olivieri A, Marchetti M, Lemoli RM, et al. on behalf of the Italian Group for Stem Cell Transplantation (GITMO). Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: An analytic hierarchy process by an ad-hoc Working Group Gruppo ItalianoTrapianto di Midollo Osseo (GITMO). Bone Marrow Transplant 2012;47:342-51
   PubMed Web of Science ®Google Scholar
• Publicover A, Richardson DS, Davies A, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol 2013;162(1):107-11
   PubMed Web of Science ®Google Scholar
• Di Persio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6
   PubMed Web of Science ®Google Scholar
• Di Persio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73
   PubMed Web of Science ®Google Scholar
• Attolico I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate pbsc collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012;18(2):241-9
   PubMed Web of Science ®Google Scholar
• Lanza F, Lemoli RM, Olivieri A, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 2013;54(2):331-9
   PubMed Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvementin peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Fischmeister G, Kurz M, Haas OA, et al. G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Ann Hematol 1999;78:117-23
   PubMed Web of Science ®Google Scholar
• Sohn SK, Kim JG, Seo KW, et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;30:81-6
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995;85(6):1655-8
   PubMed Web of Science ®Google Scholar
• Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilization in a healthy donor. Lancet 1999;353(9152):555
   PubMed Web of Science ®Google Scholar
• Martino M, Massara E, Irrera G, et al. Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells. Bone Marrow Transplant 2012;47(2):308-10
   PubMed Web of Science ®Google Scholar
• Martino M, Fedele R, Massara E, et al. Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear? Expert Opin Biol Ther 2012;12(5):609-21
   PubMed Web of Science ®Google Scholar
• Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96(7):937-42
   PubMed Web of Science ®Google Scholar
• Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011;96(7):942-7
   PubMed Web of Science ®Google Scholar
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Clinical. Trials.gov Identifier. NCT00241358. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01403896
   Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized, double-blind, multicenter phase III study of fixed dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer. Oncol Rep 2003;10:715-24
   PubMed Web of Science ®Google Scholar
• Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-19
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Kourbeti IS. Pegfilgrastim vs filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant 2012;26:16-22
   PubMed Web of Science ®Google Scholar
• Kroschinsky F, Hölig K, Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci 2008;38(3):237-44
   PubMed Web of Science ®Google Scholar
• Rutella S, Bonanno G, Pierelli L, et al. Granulocyte colonystimulating factor promotes the generation of regulatory DCs through induction of IL-10 and IFN-alpha. Eur J Immunol 2004;34:1291-302
   PubMed Web of Science ®Google Scholar
• Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood 2006;107:3430-5
   PubMed Web of Science ®Google Scholar
• De Haan G, Ausema A, Wilkens M, et al. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000;110(3):638-46
   PubMed Web of Science ®Google Scholar
• Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-esacalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18(13):2522-8
   PubMed Web of Science ®Google Scholar
• Viens P, Chabannon C, Pouillard P, et al. Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002;20:24-36
   PubMed Web of Science ®Google Scholar
• Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-6
   PubMed Web of Science ®Google Scholar
• Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-185
   PubMed Web of Science ®Google Scholar
• Kroschinsky F, Holig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006;46:1417-23
   PubMed Web of Science ®Google Scholar
• Nosari A, Cairoli R, Ciapanna D, et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 2006;38(6):413-16
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Klaus J, Huesing J, et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007;39:743-50
   PubMed Web of Science ®Google Scholar
• Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005;90:225-31
   PubMedGoogle Scholar
• Zappasodi P, Nosari AM, Astori C, et al. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 2008;48(5):857-60
   PubMed Web of Science ®Google Scholar
• Putkonen M, Rauhala A, Pelliniemi TT, et al. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 2009;88:673-80
   PubMed Web of Science ®Google Scholar
• Simona B, Cristina R, Luca N, et al. A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 2010;43:321-6
   PubMed Web of Science ®Google Scholar
• Tricot G, Barlogie B, Zangari M, et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematological 2008;93:1739-42
   PubMed Web of Science ®Google Scholar
• Russell NH, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008;93:405-12
   PubMed Web of Science ®Google Scholar
• Willis F, Woll P, Theti D, et al. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant 2009;43(12):927-34
   PubMed Web of Science ®Google Scholar
• Malerba L, Mele A, Leopardi G, et al. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. Eur J Haematol 2006;76:436-9
   PubMed Web of Science ®Google Scholar
• Hosing C, Qazilbash MH, Kebriaei P, et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006;133(5):533-7
   PubMed Web of Science ®Google Scholar
• Merlin E, Zohar S, Jerome C, et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit? Bone Marrow Transplant 2009;43:919-25
   PubMed Web of Science ®Google Scholar
• Herbert KE, Gambell P, Link EK, et al. Pegfilgrastim compared with filgrastim for cytokinealone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant 2013;48(3):351-6
   PubMed Web of Science ®Google Scholar
• NCT00066092 - ClinicalTrials.gov
   Google Scholar
• Costa LJ, Kramer C, Hogan KR, et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012;52(11):2375-81
   PubMed Web of Science ®Google Scholar
• Hill GR, Morris ES, Fuery M, et al. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 2006;12:603-7
   PubMed Web of Science ®Google Scholar
• Kroschinsky F, Holig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005;90:1665-71
   PubMed Web of Science ®Google Scholar
• Picardi M, De Rosa G, Selleri C, et al. Spleen enlargement following recombinant human granulocyte colony- stimulating factor administration for peripheral blood stem cell mobilization. Haematologica 2003;88:794-800
   PubMedGoogle Scholar
• Kobbe G, Bruns I, Fenk R, et al. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009;43(9):669-77
   PubMed Web of Science ®Google Scholar
• Perrier L, Lefranc A, Pérol D, et al. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy 2013;11(2):129-38
   PubMedGoogle Scholar
• DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 2006;16(9):833-43
   PubMed Web of Science ®Google Scholar
• Bondarenko I, Gladkov OA, Elaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013;13(1):386
   PubMedGoogle Scholar